Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21716647 | 0.91 | L3MBTL1 (0.45) | CTSBCTSSCTSKALDH1A1L3MBTL1 | |
| SCHEMBL22352667 | 0.89 | LMNA (0.40) | LMNACTSBCTSSCTSKALDH1A1 | |
| SCHEMBL22415477 | 0.84 | LMNA (0.45) | LMNACTSBCTSSCTSKALDH1A1 | |
| SCHEMBL20879944 | 0.84 | LMNA (0.45) | LMNACTSBCTSSCTSKALDH1A1 | |
| SCHEMBL24062686 | 0.82 | CTSB (0.40) | CTSBCTSSCTSKL3MBTL1NAAA | |
| SCHEMBL18588464 | 0.80 | LMNA (0.42) | LMNACTSBCTSSCTSKALDH1A1 | |
| SCHEMBL18588460 | 0.80 | LMNA (0.42) | LMNACTSBCTSSCTSKALDH1A1 | |
| SCHEMBL21883955 | 0.80 | KMT2A (0.54) | LMNACTSBCTSSCTSKTAAR1 | |
| SCHEMBL22415478 | 0.80 | KMT2A (0.54) | LMNACTSBCTSSCTSKTAAR1 | |
| SCHEMBL21883928 | 0.79 | TAAR1 (0.40) | CTSBCTSSCTSKALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | LMNA 3156/4885CTSB 1063/4885CTSS 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.